Target RAAS for rapid map Improvement
GIAPREZA is the first and only synthetic human ANG II—the only RAAS regulator available to rapidly raise MAP in a median of 5 minutes1,2
Efficacy
Median time to reach
MAP was 5 minutes1
In a phase 3 trial of 321 patients with distributive shock who remained hypotensive despite fluid and vasopressor therapy1,3:
When GIAPREZA was added to SOC, 3x more patients achieved and sustained target MAP.1
Connect with a GIAPREZA sales
representative for information and support.
ANG=angiotensin; MAP=mean arterial pressure; RAAS=renin-angiotensin-aldosterone system; SOC=standard of care.
References:
- GIAPREZA. Prescribing information. La Jolla Pharmaceutical Company; 2021.
- National Center for Biotechnology Information. PubChem Compound Summary for CID 172198, angiotensin II. Accessed January 14, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/Angiotensin-II-human
- Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419-430. doi:10.1056/NEJMoa1704154
- Klijian A, Khanna AK, Reddy VS, et al. Treatment with angiotensin II is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: a post-hoc analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study. J Cardiothorac Vasc Anesth. 2021;35(1):51-58. doi:10.1053/j.jvca.2020.08.001
- Khalil B, Rosani A, Warrington SJ. Physiology, Catecholamines. StatPearls; 2024. Accessed December 12, 2025. https://www.ncbi.nlm.nih.gov/books/NBK507716/
- Demiselle J, Fage N, Radermacher P, et al. Vasopressin and its analogues in shock states: a review. Ann Intensive Care. 2020;10(1):9. doi:10.1186/s13613-020-0628-2
- Bellomo R, Forni LG, Busse LW, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202(9):1253-1261. doi:10.1164/rccm.201911-2172OC
- Buckley MS, Barletta JF, Smithburger PL, et al. Catecholamine vasopressor support sparing strategies in vasodilatory shock. Pharmacotherapy. 2019;39(3):382-398. doi:10.1002/phar.2199
- Supplementary appendix to: Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419-430. doi:10.1056/NEJMoa1704154
IMPORTANT SAFETY INFORMATION
Indication
GIAPREZA® (angiotensin II) increases blood pressure in adults with septic or other distributive shock.
Contraindications
None.
Warnings and Precautions
The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.
Adverse Reactions
The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.
Drug Interactions
Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.
You are encouraged to report negative side effects of prescription drugs to the FDA.
To report SUSPECTED ADVERSE REACTIONS, please contact:
Before administering, please see the Full Prescribing Information for GIAPREZA.